BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Capsaicin (Qutenza) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Capsaicin (Qutenza)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07122973-8745@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capsaicin (Qutenza): Phase na readout est. (NCT07122973)
DESCRIPTION:Capsaicin (Qutenza)\, phase na.\nStudy: Topographical Distribut
 ion of Itch and Pain Receptors\nEstimated primary completion: 31 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/capsaicin-quten
 za#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7122973
URL:https://assetmemo.bio/drug/capsaicin-qutenza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07602387-8745@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Capsaicin (Qutenza): Phase na readout est. (NCT07602387)
DESCRIPTION:Capsaicin (Qutenza)\, phase na.\nStudy: Chemotherapy Induced Pe
 ripheral Neuropathy by Taxanes and Capsaicin 8%.\nEstimated primary comple
 tion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cap
 saicin-qutenza#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07602387
URL:https://assetmemo.bio/drug/capsaicin-qutenza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06023706-8745@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270508
DTEND;VALUE=DATE:20270509
SUMMARY:Capsaicin (Qutenza): Phase 3 readout est. (NCT06023706)
DESCRIPTION:Capsaicin (Qutenza)\, phase 3.\nStudy: Study Evaluating the Ana
 lgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia.\nEstimate
 d primary completion: 8 May 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/capsaicin-qutenza#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06023706
URL:https://assetmemo.bio/drug/capsaicin-qutenza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06744816-8745@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Capsaicin (Qutenza): Phase 1 readout est. (NCT06744816)
DESCRIPTION:Capsaicin (Qutenza)\, phase 1.\nStudy: Exploring the Benefit of
  Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropat
 hy: a Longitudinal Single Center Pilot Study\nEstimated primary completion
 : 30 November 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 apsaicin-qutenza#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06744816
URL:https://assetmemo.bio/drug/capsaicin-qutenza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06444919-8745@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Capsaicin (Qutenza): Phase 4 readout est. (NCT06444919)
DESCRIPTION:Capsaicin (Qutenza)\, phase 4.\nStudy: Capsaicin in Digital Ost
 eoarthritis Versus Control\nEstimated primary completion: 1 January 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/capsaicin-qutenza#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0644491
 9
URL:https://assetmemo.bio/drug/capsaicin-qutenza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05840562-8745@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Capsaicin (Qutenza): Phase 3 readout est. (NCT05840562)
DESCRIPTION:Capsaicin (Qutenza)\, phase 3.\nStudy: Capsaicin 179 mg Patch V
 ersus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neu
 ropathy\nEstimated primary completion: March 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/capsaicin-qutenza#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05840562
URL:https://assetmemo.bio/drug/capsaicin-qutenza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07660510-8745@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Capsaicin (Qutenza): Phase na readout est. (NCT07660510)
DESCRIPTION:Capsaicin (Qutenza)\, phase na.\nStudy: Evolution of Different 
 Sensitivity Levels in Patients With Chronic Neuropathic Pain in the Pelvi-
 perineal Region After Treatment With High-concentration Capsaicin Patches\
 nEstimated primary completion: 1 March 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/capsaicin-qutenza#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07660510
URL:https://assetmemo.bio/drug/capsaicin-qutenza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05997979-8745@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Capsaicin (Qutenza): Phase 3 readout est. (NCT05997979)
DESCRIPTION:Capsaicin (Qutenza)\, phase 3.\nStudy: Analgesic Effectiveness 
 of Capsaicin 8% Cutaneous Patch in Children\nEstimated primary completion:
  5 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capsaic
 in-qutenza#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05997979
URL:https://assetmemo.bio/drug/capsaicin-qutenza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
